Dravya Discovery provides preclinical in vitro research services focused on ophthalmology drug discovery and early translational research. Our services include human cell-based disease models, assay development, target validation, mechanistic studies, and efficacy testing across a range of ocular indications.
We support research across multiple ophthalmic indications, including:
We can also develop custom disease models tailored to specific research questions.
We use human-relevant cell-based models to replicate key disease mechanisms in the eye. These may include:
These models help evaluate drug efficacy, mechanism of action, and safety signals early in the discovery process.
Yes. In addition to established assays, we frequently develop bespoke experimental models and assays designed around specific drug targets, pathways, or therapeutic mechanisms.
Our scientists work closely with clients to ensure the assay captures relevant disease biology and delivers actionable data.
We support testing across a wide range of therapeutic modalities including:
Our assays can be adapted to evaluate mechanism, potency, and functional activity for these modalities.
Depending on the study design, we can measure:
Functional activity assays
Project timelines vary depending on complexity, but typical timelines are:
We provide clear project timelines and milestones at the proposal stage.
We follow rigorous experimental practices including:
Our goal is to deliver high-confidence, decision-ready datasets.
We encourage close collaboration. Clients typically receive:
Opportunity to discuss results directly with our scientists
Yes. Many of our projects involve confidential early-stage therapeutic programmes. We routinely work under NDAs and strict confidentiality agreements to ensure client IP protection.
Yes. Our clients include biotech companies, pharmaceutical companies, academic groups, and venture-backed start-ups working on innovative ophthalmology therapeutics.
To begin a collaboration: